Jonathan David Schwartz - 18 Nov 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Chief Science & Gene Therapy Officer
Issuer ticker: RCKT
Reported as of: 18 Nov 2025
Net transaction value: -$7,592
SEC form: 4
Accepted by SEC: 20 Nov 2025, 16:05:38 UTC
Prior SEC filing: 09 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz

Key filing fact

Jonathan David Schwartz filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 20 Nov 2025.

Key facts

This page summarizes Jonathan David Schwartz's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Nov 2025, 16:05.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001726398 Primary reporting owner

Relationship: Chief Science & Gene Therapy Officer
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz
Signature date: 20 Nov 2025

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Sale

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

SEC remarks

Chief Science & Gene Therapy Officer